
Bolt Biotherapeutics (NASDAQ:BOLT) brought in sales totaling $508.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 16.08%, resulting in a loss of $27.16 million. Bolt Biotherapeutics collected $752.00 thousand in revenue during Q3, but reported earnings showed a $23.39 million loss.